19 April 2010 in Journal of Controlled Release
17 February 2017 in MedChemComm
Natural prenylated indoles have been proposed as potential anticancer agents. To exploit this discovery for developing new peptide therapeutics, we report the first studies whereby incorporation of prenylated indoles into primary sequences has been achieved. We developed a route to synthesise Nα-Fmoc-protected tryptophan derivatives in which the prenyl group is linked to the N-indole core, using Pd(II)-mediated C–H functionalisation of 2-methyl-2-butene. Based on the Substance P antagonist G (SPG), a well-known Small Cell Lung Cancer (SCLC) anticancer agent, we designed a new penta-peptide sequence to include a prenyl moiety on one of the tryptophan residues. The N-tert-prenylated tryptophan analogue was assembled into the pentameric peptide using standard solid phase peptide synthesis or liquid phase synthesis by fragment coupling. In vitro screening showed that the N-tert-prenylation of the indole ring on the tryptophan residue located near the C-terminal of the penta-peptide enhanced the cytotoxicity against H69 (IC50 = 2.84 ± 0.14 μM) and DMS79 (IC50 = 4.37 ± 0.44 μM) SCLC cell lines when compared with the unmodified penta-peptide (H69, IC50 = 30.74 ± 0.30 μM and DMS79, IC50 = 23.00 ± 2.07 μM) or the parent SPG sequence (IC50 > 30 μM, both cell lines). SCLC almost invariably relapses with therapy-resistant disease. The DMS79 cell line was established from a patient following treatment with a number of chemotherapeutics (cytoxan, vincristine and methotrexate) and radiation therapy. Treating DMS79 tumour-bearing nude mice provided a human xenograft model of drug resistance to test the efficacy of the prenylated peptide. A low dose (1.5 mg kg−1) of the prenylated peptide was found to reduce tumour growth by ∼30% (P < 0.05) at day 7, relative to the control group receiving vehicle only. We conclude that the availability of the Fmoc-Trp(N-tert-prenyl)-OH amino acid facilitates the synthesis of prenylated-tryptophan-containing peptides to explore their therapeutic potential.
21 April 2002 in Biochimica et Biophysica Acta (BBA) - Biomembranes
18 July 2016 in RSC Advances
Contradictions in the reported biocompatibility of graphene-related materials have been attributed to differences in their preparation. Herein, we address the conflicting behavior of different pristine graphene dispersions through their careful preparation and characterization in aqueous media. Although exfoliated in different media, all graphene dispersions were physically similar and comprised few-layer graphene flakes of 100 to 400 nm mean length with relatively defect-free basal planes. The dispersions were colloidally stable, including in physiological saline and when organic solvents were exchanged with water by dialysis, due to their negative zeta potentials (−28 mV to −60 mV) from interaction with water and the different dispersants. Thus, we have been able to establish the influence of pre-association with different dispersants, including those likely to be encountered during the transport and excretion of graphene in vivo. Shear-forced association with neutral phospholipids was transient, as the lipids desorbed to form liposomes, and left a hemolytic dispersion, whereas other dispersions were not hemolytic. High boiling point solvents widely used to exfoliate graphene are toxic and viewed difficult to remove, but were readily removed by simple dialysis. Human serum albumin readily and stably adsorbed in predominantly monomeric form to pristine graphene in physiological saline, which may be expected in vivo. This work shows the large influence that different adsorbates can have on the behaviour of otherwise physically-similar graphene.
20 December 2013 in RSC Advances
Using a previously-characterised solid tumour model we demonstrate that a mixture of pH sensitive peptide and liposome nanoparticles (PLNs) can be used to induce payload release in response to small changes in tumour acidity. The classical pH sensitive GALA peptide was modified at two different positions to help tether with preformed liposomes and cause release of calcein marker in response to a less than 1.0 unit drop in pH from the physiological value. The circular dichroic spectra of the peptide showed that, unlike the GALA sequence, its helical structure was unusually independent of pH suggesting a different mechanism of action for calcein release. Intravenously-administered PLNs accumulated in tumour tissue in mice, and subjecting the excised tumour tissue slices to low pH buffer confirmed that these nanoparticles remained pH responsive. Quantitative in vivo imaging of tumours implanted in mouse dorsal skin allowed real time measurements of nanoparticle accumulation, monitored through DiI labelling of the liposome membrane, and intra-tumour pH dependent release, monitored by calcein release, to be followed. The release of calcein in the live tumours at their natural acidity of pH 6.8 was further enhanced with MIBG glucose treatment to induce tumour acidification to approximately pH 6.5. Following accumulation a substantially greater and more rapid calcein release was observed in tumours administered with PLNs and subjected to pH-lowering using MIBG treatment, compared to control tumours administered with liposomes lacking the peptide or tumours not treated with MIBG. This work highlights that while PLNs were relatively unresponsive to intrinsic tumour pH, they did have the ability to respond rapidly to extrinsically-induced small changes in pH near the patho-physiological range.